Talks highlight efficacy, durability, and safety of Nanoscope’s MCO (multi-characteristic opsin) optogenetic therapy platform
Data forms the foundation for recent rolling Biologics License Application submission with the FDA for retinitis pigmentosa
Nanoscope Therapeutics Inc., a biotechnology company committed to developing and commercializing novel disease-agnostic therapies for patients with photoreceptor loss and vision impairment from retinal degeneration, will present compelling new data from its RESTORE long-term follow-up study, REMAIN, at the 2025 Euretina Congress and Retina Society Annual Scientific Meeting. The presentations highlight positive 152-week efficacy and safety results for MCO-010 (sonpiretigene isteparvovec), the company’s lead optogenetic therapy for retinitis pigmentosa (RP). MCO-010, delivered as a one-time, in-office intravitreal injection, is the first and only therapy in a randomized, controlled trial shown to restore vision in RP patients with severe vision loss.
“Durable efficacy and long-term tolerability are meaningful for patients suffering from irreversible, progressive vision loss due to RP, and underscore the potential of MCO-010 to redefine the standard of care for these patients.”, said Dr. Samarendra Mohanty, President and Chief Scientific Officer, Nanoscope. “It is an exciting time at Nanoscope as we prepare MCO-010 for commercialization, kicked off by the recent initiation of our rolling BLA with the FDA.”
Discover the latest trends and insights—explore the Business Insights Journal for up-to-date strategies and industry breakthroughs!
